Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 2Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Neoplasm Metastasis 3Pain 2Breast Neoplasms 2Bone Neoplasms 2Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 5Nivolumab 3Irinotecan 3Ipilimumab 3Docetaxel 3Cyclophosphamide 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3pegfilgrastim 2Vincristine 2Temozolomide 2Ibandronic Acid 2Everolimus 2Doxorubicin 2CTLA-4 Antigen 2spartalizumab 1saracatinib 1samarium Sm-153 lexidronam 1pembrolizumab 1palbociclib 1liposomal doxorubicin 1lenvatinib 1fludarabine 1anlotinib 1angiotensin I (1-7) 1aldesleukin 1Zoledronic Acid 1Trabectedin 1Topotecan 1Taxes 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Bone Neoplasms × Ibandronic Acid × Clear all
NCT00478270 2017-08-16

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

Hoffmann-La Roche

Phase 2 Withdrawn
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

NCT00502736 2014-01-22

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.

Hoffmann-La Roche

Phase 2 Completed
13 enrolled
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡